≥99% HPLCPre-filled pen

Retatrutide

Name: Retatrutide
Brand: Dripfy
Availability: InStock

What it is?

Retatrutide is a multi-pathway metabolic agonist studied for combined engagement of GLP-1, GIP, and glucagon receptors, positioning it for comprehensive body-weight and metabolic endpoint research. By targeting multiple nodes in energy balance regulation, it is commonly framed as an advanced option in protocols focused on appetite signalling, glycaemic control, and energy expenditure dynamics.

Dripfy Advantage

Triple receptor engagement: Activates GLP-1R, GIPR, and glucagon receptors, supporting broad incretin–glucagon axis modulation.
Appetite & satiety modulation: Associated with reduced hunger signalling and improved satiety-related behavioural endpoints through central mechanisms.
Energy expenditure dynamics: Glucagon-receptor engagement is positioned to support increased energy expenditure and fat-oxidation signalling endpoints.
Glucose–insulin regulation: Supports improvements in glycaemic control and insulin sensitivity markers through coordinated endocrine pathway effects.
Comprehensive metabolic coverage: Designed for protocols where multiple metabolic levers (intake + expenditure + glucose control) are monitored simultaneously.

Clinical Applications & Therapeutic Potential

Weight-reduction endpoints: Potential for substantial reductions in body-weight and fat-mass endpoints in structured protocols (context-dependent).
Insulin sensitivity & glycaemic markers: Potential improvements in insulin sensitivity indices and glucose regulation endpoints.
Energy balance optimisation: Potential support for increased fat oxidation markers and improved energy expenditure dynamics.
Stubborn obesity research positioning: Often positioned as potentially more impactful than single-pathway agonists for resistant obesity endpoints (protocol-dependent).

Composition & Formulation

Peptide Content: 6 mg or 12 mg Retatrutide
Vehicle: Proprietary pH-balanced buffer solution
Delivery System: Pre-filled, multi-dose, closed-system pen
Total Volume: 3 mL
Purity: ≥99% by HPLC/MS

€534

Order by email

Submit an enquiry and we arrange the consultation, physician review and shipping. Physician recommendation required; not medical advice.

Purity: ≥99%
Form: Pre-filled pen
Download Certificate of Analysis: Certificate of Analysis available on request

Important medical notice

A physician recommendation is mandatory before use.
The information on this website is educational only and is not medical advice, diagnosis, or treatment.
Always consult a qualified physician before starting any peptide.
Dosing is individualised and determined by your treating physician.

Peptide Practice Guide

Each card summarises what the peptide is studied for and its evidence strength. It is not a recommendation. Dosing and suitability are decided by your physician.

Retatrutide

Triple GLP-1/GIP/glucagon receptor agonist (investigational) · Pre-filled pen

B· Moderate evidence

Retatrutide is an investigational triple agonist designed to engage GLP-1, GIP and glucagon receptors. The GLP-1 and GIP actions influence insulin secretion, appetite and satiety, while glucagon-receptor activation is studied for its potential to increase energy expenditure and fat oxidation. It is being evaluated in advanced clinical trials for weight and metabolic endpoints.

Studied use areas

Body-weight reduction under clinical-trial investigation
Glycaemic-control research
Appetite and satiety signalling
Energy-expenditure and fat-oxidation endpoints

Safety & status

Investigational agent that is not yet approved; as a GLP-1-class compound it would be prescription-only in the EU and UK (EMA/MHRA) and requires physician supervision
Gastrointestinal effects seen with incretin agonists (nausea, vomiting, diarrhoea) are expected during trials
Long-term safety is not yet established outside the clinical-trial setting
No dosing is provided here; any regimen is individualised and determined by the treating physician

⚕ Clinical note: This is educational information, not medical advice. Retatrutide is an investigational, late-phase compound; it is not an approved product, and any exposure should occur only under qualified physician supervision within an appropriate clinical framework.

Evidence: Grade B — investigational, late-phase compound with promising controlled-trial data · References: Phase 2/3 multi-receptor incretin agonist clinical-trial literature; Peer-reviewed GLP-1/GIP/glucagon receptor agonist research; EMA/MHRA regulatory guidance on incretin-class agents